Tempest rises as company eyes potential merger to advance liver cancer drug

ReutersApr 9, 2025 9:12 PM

Shares of cancer drug developer Tempest Therapeutics TPST.O rise ~9% to $7.79 in extended trading

TPST says it is exploring strategic alternatives, such as mergers or partnerships, to advance its cancer treatment programs

Company's pipeline includes its lead liver cancer drug, amezalpat, and TPST-1495, a treatment for familial adenomatous polyposis, a rare genetic disorder

Amezalpat received both Orphan Drug and Fast Track designations from the US FDA

As of last close, stock down 34% YTD

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Recommended Articles

U.S.-Iran Saturday Pakistan Talks Preview: What Is the Impact on Assets If Negotiations Fail?

TradingKey — Following five weeks of military conflict, the U.S. and Iran are scheduled to formally launch their first round of direct talks on the morning of April 11, local time, in Islamabad, Pakistan. This marks the third set of negotiations between the two nations within a year. During the previous two negotiation processes, sudden military actions were launched by the U.S. and Israel against Iran.

SpaceX IPO Analysis: Why Terafab and Grok are the Real Reasons to Invest in SpaceX

TradingKey - Investors are mainly focused on SpaceX's launch operations and Starlink, which have both generated a lot of revenue and cash flow for the company. However, one of the potential drivers of long-term growth for SpaceX is likely to be overlooked, but may also be one of the biggest componen

Coinbase Stock Price Prediction 2026–2030: Is a $1,000 Target Realistic?

Coinbase is currently navigating a "tempestuous two-step" between retail speculation and institutional infrastructure. For those tracking the Coinbase share price, the short term will remain sensitive to Bitcoin’s cycles and geopolitical headlines.

Michael Burry says Anthropic is 'Eating Palantir's Lunch', is Palantir Still a buy?

TradingKey - PLTR drops over 7% on Burry's Anthropic enterprise data. Maven Program of Record, $142x valuation risk, and $125 support level analysed.

Anthropic Claude Mythos Preview Sparks Wall Street Panic: Bessent, Powell Summon CEOs; Cloudflare Tumbles 8%

TradingKey - According to the latest Bloomberg report, U.S. Treasury Secretary Bessent and Federal Reserve Chair Jerome Powell urgently convened a meeting with the CEOs of major Wall Street banks this Tuesday to discuss potential cybersecurity threats posed by Anthropic's latest AI model, Mythos. Th

Featured Tools